EA201691835A1 - ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B - Google Patents

ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B

Info

Publication number
EA201691835A1
EA201691835A1 EA201691835A EA201691835A EA201691835A1 EA 201691835 A1 EA201691835 A1 EA 201691835A1 EA 201691835 A EA201691835 A EA 201691835A EA 201691835 A EA201691835 A EA 201691835A EA 201691835 A1 EA201691835 A1 EA 201691835A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
allasteric
modulators
capside protein
capside
Prior art date
Application number
EA201691835A
Other languages
Russian (ru)
Inventor
Уилльям У. Тернер
Ли Дэниел Арнольд
Ханс Мааг
Адам Злотник
Original Assignee
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Ассембли Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн, Ассембли Байосайенсиз, Инк. filed Critical Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Priority claimed from PCT/US2015/020444 external-priority patent/WO2015138895A1/en
Publication of EA201691835A1 publication Critical patent/EA201691835A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/14—[b, e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение представляет, в частности, соединения, обладающие свойствами аллостерического эффектора в отношении вируса Cp гепатита B. Также в настоящем описании представлены способы лечения вирусных инфекций, таких как гепатит B, включающие введение пациенту, нуждающемуся в таком лечении, раскрытого соединения.The present invention provides, in particular, compounds having the properties of an allosteric effector against hepatitis B Cp virus. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need of such treatment the disclosed compound.

EA201691835A 2014-06-10 2015-03-13 ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B EA201691835A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462010025P 2014-06-10 2014-06-10
PCT/US2015/020444 WO2015138895A1 (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Publications (1)

Publication Number Publication Date
EA201691835A1 true EA201691835A1 (en) 2020-01-23

Family

ID=69374448

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691835A EA201691835A1 (en) 2014-06-10 2015-03-13 ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B

Country Status (1)

Country Link
EA (1) EA201691835A1 (en)

Similar Documents

Publication Publication Date Title
PH12018500573A1 (en) Hepatitis b core protein modulators
MX2019003525A (en) Hepatitis b core protein allosteric modulators.
MX2023013140A (en) Vaccines against hepatitis b virus.
NZ730809A (en) Methods for treating filoviridae virus infections
EA201791515A1 (en) COMPOUNDS OF PYRAZINE FOR THE TREATMENT OF INFECTIOUS DISEASES
EA201691726A1 (en) NEW 6-CONDENSED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201791460A1 (en) N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
MX2017008720A (en) Derivatives and methods of treating hepatitis b infections.
EA201691261A1 (en) NEW DIHYDROCHINOLYSINES FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY THE HEPATITIS B VIRUS
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
EA201790700A1 (en) MONO OR DESIGNED INDOLS AS AN INHIBITORS REPLICATION OF DENG VIRUSES
MX2017000312A (en) Isoindoline derivatives for use in the treatment of a viral infection.
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
EA201690594A1 (en) COMPOSITION FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ATAZANAVIR AND COBICISTAT
EA201590297A1 (en) HETEROCYCLIC CARBOXAMIDES FOR THE TREATMENT OF VIRAL DISEASES
EA201790771A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FOR THE TREATMENT OF HEPATITIS C
EA201790776A1 (en) COMBINED COMPOSITIONS OF LONG-TERM ACTIONS AND METHODS OF TREATING HEPATITIS C
EA201691835A1 (en) ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B
BR112016020895A2 (en) Hepatitis B Core Allosteric Protein Modulators
TR201910305T4 (en) Compounds to treat viral infections.
TH1601005264A (en)
EA201791356A1 (en) PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS